Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 17720.0
(-0.11%)
KRW 17720.0
(-0.11%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 118.63 Billion KRW | 35.57% |
| 2022 | 87.51 Billion KRW | 60.56% |
| 2021 | 54.5 Billion KRW | 558.64% |
| 2020 | 8.27 Billion KRW | 455.78% |
| 2019 | 1.48 Billion KRW | 0.0% |
| 2018 | - KRW | -100.0% |
| 2017 | 4 Billion KRW | -55.56% |
| 2016 | 9 Billion KRW | -68.97% |
| 2015 | 29 Billion KRW | -12.12% |
| 2014 | 33 Billion KRW | -30.53% |
| 2013 | 47.5 Billion KRW | 10.47% |
| 2012 | 43 Billion KRW | -3.24% |
| 2011 | 44.44 Billion KRW | 8.39% |
| 2010 | 41 Billion KRW | -23.08% |
| 2009 | 53.3 Billion KRW | 11.2% |
| 2008 | 47.93 Billion KRW | 33.68% |
| 2007 | 35.85 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 111.21 Billion KRW | -6.25% |
| 2024 Q2 | 114.09 Billion KRW | 2.59% |
| 2023 Q4 | 118.63 Billion KRW | 5.68% |
| 2023 Q1 | 94.48 Billion KRW | 7.97% |
| 2023 Q2 | 112.32 Billion KRW | 18.88% |
| 2023 FY | 118.63 Billion KRW | 35.57% |
| 2023 Q3 | 112.25 Billion KRW | -0.06% |
| 2022 Q4 | 87.51 Billion KRW | 4.54% |
| 2022 Q2 | 83.9 Billion KRW | 11.96% |
| 2022 Q1 | 74.93 Billion KRW | 37.49% |
| 2022 FY | 87.51 Billion KRW | 60.56% |
| 2022 Q3 | 83.7 Billion KRW | -0.23% |
| 2021 Q3 | 38.85 Billion KRW | 38.15% |
| 2021 Q2 | 28.12 Billion KRW | 58.84% |
| 2021 FY | 54.5 Billion KRW | 558.64% |
| 2021 Q1 | 17.7 Billion KRW | 113.95% |
| 2021 Q4 | 54.5 Billion KRW | 40.29% |
| 2020 FY | 8.27 Billion KRW | 455.78% |
| 2020 Q3 | 8.13 Billion KRW | 3.67% |
| 2020 Q4 | 8.27 Billion KRW | 1.75% |
| 2020 Q1 | 1.5 Billion KRW | 0.99% |
| 2020 Q2 | 7.84 Billion KRW | 421.7% |
| 2019 Q4 | 1.48 Billion KRW | -11.76% |
| 2019 Q3 | 1.68 Billion KRW | 479.22% |
| 2019 FY | 1.48 Billion KRW | 0.0% |
| 2019 Q1 | 281.24 Million KRW | 0.0% |
| 2019 Q2 | 291.31 Million KRW | 3.58% |
| 2018 Q1 | 3 Billion KRW | -25.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2018 Q2 | - KRW | -100.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 FY | - KRW | -100.0% |
| 2017 Q3 | 4 Billion KRW | 0.0% |
| 2017 Q2 | 4 Billion KRW | -55.56% |
| 2017 Q1 | 9 Billion KRW | 0.0% |
| 2017 FY | 4 Billion KRW | -55.56% |
| 2017 Q4 | 4 Billion KRW | 0.0% |
| 2016 Q1 | 19 Billion KRW | -34.48% |
| 2016 Q3 | 9 Billion KRW | -47.06% |
| 2016 Q2 | 17 Billion KRW | -10.53% |
| 2016 Q4 | 9 Billion KRW | 0.0% |
| 2016 FY | 9 Billion KRW | -68.97% |
| 2015 FY | 29 Billion KRW | -12.12% |
| 2015 Q4 | 29 Billion KRW | -6.45% |
| 2015 Q3 | 31 Billion KRW | -8.82% |
| 2015 Q2 | 34 Billion KRW | 6.25% |
| 2015 Q1 | 32 Billion KRW | -3.03% |
| 2014 Q2 | 39 Billion KRW | -2.5% |
| 2014 Q3 | 36 Billion KRW | -7.69% |
| 2014 FY | 33 Billion KRW | -30.53% |
| 2014 Q4 | 33 Billion KRW | -8.33% |
| 2014 Q1 | 40 Billion KRW | -15.79% |
| 2013 Q3 | 51.5 Billion KRW | -4.63% |
| 2013 Q4 | 47.5 Billion KRW | -7.77% |
| 2013 FY | 47.5 Billion KRW | 10.47% |
| 2013 Q1 | 41 Billion KRW | -4.65% |
| 2013 Q2 | 54 Billion KRW | 31.71% |
| 2012 Q2 | 28 Billion KRW | -28.21% |
| 2012 Q1 | 39 Billion KRW | -12.24% |
| 2012 FY | 43 Billion KRW | -3.24% |
| 2012 Q4 | 43 Billion KRW | 59.26% |
| 2012 Q3 | 27 Billion KRW | -3.57% |
| 2011 Q3 | 59.15 Billion KRW | 9.34% |
| 2011 Q4 | 44.44 Billion KRW | -24.88% |
| 2011 FY | 44.44 Billion KRW | 8.39% |
| 2011 Q1 | 55.61 Billion KRW | 35.64% |
| 2011 Q2 | 54.1 Billion KRW | -2.71% |
| 2010 Q4 | 41 Billion KRW | -8.89% |
| 2010 Q3 | 45 Billion KRW | -9.09% |
| 2010 FY | 41 Billion KRW | -23.08% |
| 2010 Q1 | 54.9 Billion KRW | 3.0% |
| 2010 Q2 | 49.5 Billion KRW | -9.84% |
| 2009 Q2 | 49.91 Billion KRW | -0.04% |
| 2009 FY | 53.3 Billion KRW | 11.2% |
| 2009 Q4 | 53.3 Billion KRW | -0.97% |
| 2009 Q3 | 53.82 Billion KRW | 7.83% |
| 2009 Q1 | 49.93 Billion KRW | 4.17% |
| 2008 Q4 | 47.93 Billion KRW | 0.0% |
| 2008 Q2 | 41.77 Billion KRW | -0.19% |
| 2008 Q1 | 41.85 Billion KRW | 16.73% |
| 2008 Q3 | 47.93 Billion KRW | 14.74% |
| 2008 FY | 47.93 Billion KRW | 33.68% |
| 2007 Q1 | 31.51 Billion KRW | 0.0% |
| 2007 FY | 35.85 Billion KRW | 0.0% |
| 2007 Q4 | 35.85 Billion KRW | -8.89% |
| 2007 Q3 | 39.35 Billion KRW | 12.4% |
| 2007 Q2 | 35.01 Billion KRW | 11.11% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -18671.131% |
| Yuhan Corporation | 230.07 Billion KRW | 48.434% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -77.384% |
| Boryung Corporation | 204.21 Billion KRW | 41.905% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 49.653% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -9092.996% |
| CKD Bio Corp. | 146.92 Billion KRW | 19.253% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -201.058% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 68.948% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 82.853% |
| Yuhan Corporation | 230.07 Billion KRW | 48.434% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 30.328% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 46.016% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 30.328% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -19822.952% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 74.652% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -174.164% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 31.435% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -286.922% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 34.453% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 18.769% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -39.313% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -31.118% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -157.063% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 74.741% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 47.284% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -201.058% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -347.134% |
| HANDOK Inc. | 300.01 Billion KRW | 60.455% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 70.829% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 79.29% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 74.642% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -201.058% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -49721.665% |
| JW Holdings Corporation | 554.58 Billion KRW | 78.608% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 45.539% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 30.328% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -202.611% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 32.546% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -39.631% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -157.063% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -194.103% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -145.855% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -49.443% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -39.313% |
| JW Lifescience Corporation | 46.31 Billion KRW | -156.167% |